非诺贝特联合他汀类药物对冠心病合并高脂血症患者心功能及血脂指标的影响

doi:10.3969/j.issn.1671-7171.2023.11.034

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1233 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨非诺贝特联合他汀类药物对冠心病合并高脂血症患者心功能及血脂指标的影响。【方法】选择2019年1月至2021年12月通用环球西安北环医院收治的120例冠心病合并高脂血症患者,根据随机数字表法将其分为观察组和对照组,每组60例。对照组口服瑞舒伐他汀,观察组在对照组基础上口服非诺贝特。比较两组治疗效果、治疗前后心功能指标、血清炎症指标、血脂指标变化以及不良反应发生情况。【结果】观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组左心室舒张末期内经(LVEDD)低于治疗前,左室射血分数(LVEF)、心排血量(CO)高于治疗前,观察组LVEDD低于对照组,LVEF、CO高于对照组,差异均有统计学意义(P<0.05);两组高敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组总胆固醇(TG)、甘油三酯(TC)、低密度脂蛋白胆固醇(LDL-C)低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。【结论】临床应用非诺贝特联合瑞舒伐他汀治疗冠心病合并高脂血症的效果优于单用瑞舒伐他汀治疗,可有效提高患者心功能,改善患者血清炎症因子以及血脂水平。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	何海霞
	魏王芬

关键词 ：冠心病/并发症, 高脂血症/并发症, 非诺贝特/治疗应用, 羟甲基戊二酰基CoA还原酶抑制剂, 心脏功能试验

Abstract：【Objective】To investigate the effect of fenofibrate combined with statins on cardiac function and serum lipid levels in patients with coronary heart disease and hyperlipidemia. 【Methods】A total of 120 patients with CHD and hyperlipidemia admitted to Genertec Universal Xi'an Beihuan Hospital from January 2019 to December 2021 were selected and divided into an observation group and a control group according to a random number table method,with 60 cases in each group. The control group was treated with rosuvastatin,while the observation group was treated with fenofibrate in addition to the control group. The therapeutic effects,changes in cardiac function indicators,serum inflammatory indicators,and serum lipid levels before and after treatment,as well as the incidence of adverse reactions,were compared between the two groups. 【Results】The total effective rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05). After treatment,the left ventricular end-diastolic diameter(LVEDD) in both groups was lower than that before treatment,while the left ventricular ejection fraction(LVEF) and cardiac output(CO) were higher than before treatment. The LVEDD in the observation group was lower than that in the control group,while the LVEF and CO were higher than those in the control group,and the differences were statistically significant(P<0.05). The levels of high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),and interleukin-6(IL-6) in both groups were lower than those before treatment,and the observation group was lower than the control group,and the differences were statistically significant(P<0.05). The total cholesterol(TG),triglyceride(TC),and low-density lipoprotein(LDL-C) levels in both groups were lower than those before treatment,and the observation group was lower than the control group,and the differences were statistically significant(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). 【Conclusion】 The clinical application of fenofibrate combined with rosuvastatin in the treatment of coronary heart disease with hyperlipidemia is better than the use of rosuvastatin alone,which can effectively improve the patient's cardiac function,improve serum inflammatory factors,and improve serum lipid levels.

Key words： Coronary Disease/CO Hyperlipidemias/CO Fenofibrate/TU Hydroxymethylglutaryl-CoA Reductase Inhibitors Heart Function Tests

收稿日期: 2022-10-21

中图分类号:

R541.4

通讯作者: * E-mail:fangxiang369258@163.com

引用本文:

何海霞, 魏王芬. 非诺贝特联合他汀类药物对冠心病合并高脂血症患者心功能及血脂指标的影响[J]. 医学临床研究, 2023, 40(11): 1730-1733.
HE Haixia, WEI Wangfen. Observation on the Effect of Fenofibrate Combined with Statins on the Cardiac Function and Blood Lipid Levels in Patients with Coronary Heart Disease and Hyperlipidemia. JOURNAL OF CLINICAL RESEARCH, 2023, 40(11): 1730-1733.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.11.034 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I11/1730

[1] 郭丽娟,陆芳,扈晓霞,等. 不同剂量瑞舒伐他汀钙对老年冠心病合并高脂血症患者的有效性和安全性分析[J].中华老年医学杂志,2019,38(5):315-318.
[2] 金继斌,谢敬东. 辛伐他汀联合复方丹参滴丸治疗冠心病合并高脂血症64例临床疗效观察[J].智慧健康,2019,5(2):106-108.
[3] 刘云娣,张璐,孙伟鹏,等. 血脂康治疗冠心病合并高脂血症降脂效果的系统评价[J].中国中医基础医学杂志,2020,26(9):1305-1311.
[4] 袁爱梅,丁东新. 瑞舒伐他汀钙治疗高脂血症合并老年冠心病的临床研究[J].重庆医学,2020,49(S02):36-38.
[5] 李建军,石文娜. 依折麦布联合非诺贝特治疗混合型高脂血症及颈动脉斑块的临床疗效及安全性[J].中国老年学杂志,2020,40(4):720-722.
[6] 中华医学会心血管病学分会介入心脏病学组,中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等.稳定性冠心病诊断与治疗指南[J].中华心血管病杂志,2018,46(9):680-694.
[7] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J].中华心血管病杂志,2016,44(10):833-853.
[8] 刘艳宾,杨树涵,陈红伟,等. 老年冠心病患者脂肪细胞因子与冠状动脉病变严重程度的相关性[J].实用医学杂志,2019,35(11):1799-1804.
[9] 黄勇,李蔚华,尹虹,等. 冠心病患者幽门螺杆菌感染与斑块特征、脂代谢、炎症反应的相关性[J].中国动脉硬化杂志,2019,27(8):713-717.
[10] ZHANG L S,ZHANG J H,FENG R,et al. Efficacy and safety of berberine alone or combined with statins for the treatment of hyperlipidemia:a systematic review and meta-analysis of randomized controlled clinical trials[J].Am J Chin Med,2019,47(4):751-767.
[11] BISWAS K,TIWARI A,JADHAV P,et al. Rosuvastatin and fenofibrate combination in the treatment of mixed hyperlipidemia:a narrative review[J].Innov J,2021,4(3):867-877.
[12] 黄小燕,张为章,张照研,等. 非诺贝特对大鼠心肌缺血再灌注损伤的保护作用及其抑制NF-κB信号通路的作用机制[J].中国新药杂志,2020,29(10):1181-1186.
[13] PARK M S,YOUN J C,KIM E J,et al. Efficacy and safety of fenofibrate-statin combination therapy in patients with inadequately controlled triglyceride levels despite previous statin monotherapy:a multicenter,randomized,double-blind,Phase Ⅳ Study-science direct[J].Clin Ther,2021,43(17):1735-1747.